Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals significant revenue decline and weak product sales, despite some positive milestones and cost reductions. The Q&A session highlights uncertainties, especially regarding partnerships and future vaccine approvals. The lack of specific guidance on key projects and the absence of new partnerships or significant positive catalysts further contribute to a negative sentiment. Given the company's small market cap, the stock price is likely to react negatively in the short term, falling within the -2% to -8% range.
Key Financial Performance
Total Revenue $239 million in Q2 2025, compared to $415 million in Q2 2024, a decrease of 42%. The decline was attributed to lower product sales and licensing revenue.
Product Sales $11 million in Q2 2025, consisting of $13 million from supply sales and negative $2 million from Nuvaxovid product sales due to the closeout of U.S. market activities and related return reserves.
Licensing, Royalties, and Other Revenue $229 million in Q2 2025, including $199 million from Sanofi and $27 million from Takeda agreements. This was driven by milestone payments and royalties.
R&D and SG&A Expenses $123 million in Q2 2025, a 41% reduction from Q2 2024. SG&A expenses were reduced by 57%, attributed to the transition of commercial activities to Sanofi and cost reduction initiatives.
Net Income $107 million or $0.62 per diluted share in Q2 2025, compared to a net loss in the same period last year. This improvement was driven by milestone payments and cost reductions.
Cash and Receivables Over $850 million at the end of Q2 2025, including a $175 million milestone payment from Sanofi to be received in Q3 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nuvaxovid BLA approval: Received BLA approval in the U.S., triggering a $175 million milestone payment to be received in Q3 2025.
COVID-flu combination vaccines: Sanofi is developing two combination vaccine candidates with Novavax's COVID vaccine and their flu vaccines, both receiving FDA fast track designation.
R21 Matrix-M malaria vaccine: Over 20 million doses sold since mid-2024, with rollouts in 12 African countries addressing malaria endemic regions.
H5N1 avian influenza vaccine: Generated robust immune responses in preclinical trials, showing potential for single-dose administration and intranasal delivery.
Sanofi partnership: Transitioned commercial activities to Sanofi for the U.S. market, with Sanofi assuming lead commercialization role for Nuvaxovid in select global markets.
Takeda partnership: Optimized partnership for the Japanese market, improving financial terms and operating model. Takeda filed for Nuvaxovid approval in June 2025.
Serum Institute partnership: R21 Matrix-M malaria vaccine rollout in 12 African countries, with over 20 million doses sold to date.
Cost reduction: Achieved a 41% reduction in combined R&D and SG&A costs compared to the same period last year.
Revenue framework update: Raised 2025 adjusted total revenue framework to $1 billion-$1.05 billion, driven by increased demand for Matrix-M and partner reimbursements.
Matrix-M adjuvant partnerships: Signed material transfer agreements with three pharmaceutical companies to explore its utility in novel indications, including oncology.
AI-driven R&D: Utilizing AI to accelerate vaccine candidate development and improve antigen design.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company faces challenges in the global vaccine market, which is expected to grow to over $75 billion by 2030. Competitive pressures and the need to differentiate products in a crowded market are significant risks.
Regulatory Hurdles: The FDA's post-marketing commitment study for Nuvaxovid adds a financial burden of $70-$90 million, though partially reimbursed by Sanofi. Regulatory requirements could delay product launches or increase costs.
Supply Chain and Manufacturing: The company is transitioning commercial activities to partners like Sanofi and Takeda, which could lead to operational inefficiencies or disruptions. Dependence on partners for manufacturing and supply chain management poses risks.
Economic Uncertainties: Revenue has declined from $415 million in Q2 2024 to $239 million in Q2 2025, indicating financial pressures. The company is also reliant on milestone payments and royalties, which are subject to partner performance.
Strategic Execution Risks: The company’s strategy to out-license and partner vaccine assets may limit its control over product development and commercialization. Additionally, the focus on a lean and agile model could impact R&D capabilities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Framework: Novavax has updated its 2025 revenue framework, now expecting adjusted total revenue of $1 billion to $1.050 billion. This excludes potential additional revenue from Sanofi supply sales, royalties, influenza COVID combination, and Matrix-M related milestones.
Cost Management: The company has updated its full-year 2025 financial guidance for combined R&D and SG&A expenses to $495 million to $545 million, including the addition of the PMC study. Multiyear targets for combined R&D and SG&A expenses, net of partner reimbursements, are $350 million for 2026 and $250 million for 2027.
Profitability Goals: Novavax aims to achieve non-GAAP profitability as early as 2027, depending on near-term partner performance.
Post-Marketing Commitment Study (PMC): The PMC study for Nuvaxovid is anticipated to occur during 2025 and 2026, with a total cost of $70 million to $90 million. Novavax will be reimbursed 70% of the total cost by Sanofi.
Matrix-M Demand: Increased demand for Matrix-M from Serum Institute for the R21 Matrix-M malaria vaccine has been noted, with year-to-date sales of 14 million doses already exceeding the 6 million doses sold in 2024.
Partnership Milestones: Novavax anticipates earning an additional $50 million in milestones from Sanofi in Q4 2025 upon the transfer of marketing authorization for the U.S. and Europe.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Will you file for approval for the 2025-2026 COVID season vaccine using JN.1, and when will the supply be ready?
A:The company intends to deliver the JN.1 vaccine for the fall season and is working on improving its shelf-life profile to at least 6 months. Regulatory filings are focused on this improvement.
Q:What is the progress and timeline for the CIC and flu partnership discussions?
A:The company is in conversations with multiple potential partners but cannot provide specific details. Sanofi has shown strong interest, and the registrational trial will be undertaken by the potential partner.
Q:Would you expect comparable data in the Sanofi study regarding CD4 T cell superiority, and how important is B strain-specific immunogenicity?
A:The company cannot comment on Sanofi's progress but is encouraged by its own data showing favorable CD4 T cell responses. B strain-specific immunogenicity is speculative and depends on circulating strains each season.
Q:What is the process for MTAs leading to financial transactions, and how does the evolving BARDA framework impact this?
A:MTAs allow potential partners to test the company's technology, which could lead to financial deals. The company is in discussions with BARDA for funding but cannot comment on specific frameworks.
Q:What is your confidence in positive efficacy data from the post-marketing Phase IV trial, and is there an interim analysis?
A:The company is confident in its data and plans to start the study by the end of the year, with data expected in subsequent quarters.
Q:Is the company open to acquiring or in-licensing clinical-stage candidates?
A:The company is focused on external partnerships and internal development of its pipeline, including exploring Matrix-M's potential in oncology.
Q:What information can you share about the design, size, and timing of the requested PMC?
A:The PMC is a post-marketing study targeting specific age populations and endpoints. It is expected to start by the end of the year, with an estimated cost of $70-90 million.
Q:How does the FDA's shifting stance on mRNA vaccines provide a tailwind for the company?
A:The company sees continued investment in vaccines by peers and believes its protein-based platform offers a strong alternative, particularly in light of recent funding shifts.
Q:Does the profitability target for 2027 assume flat worldwide COVID vaccine use?
A:The company aims for sustainable profitability by 2027, with breakeven scenarios including royalties from Sanofi's COVID vaccine sales and milestones from flu and CIC combinations.
Q:Does the company see potential for multiyear flu vaccines?
A:The company is exploring broader immune protection and longer durability but acknowledges that universal flu vaccines have not yet been successful.
Q:How does the desire for a universal vaccine impact interest in the company's flu and CIC vaccines?
A:The company does not see this as an impediment, as universal flu vaccines have not been successful despite decades of effort.
Q:What are the company's plans for oncology and other areas beyond respiratory vaccines?
A:The company is exploring Matrix-M's potential in oncology and other areas, with plans to share initial data in the coming quarters. It aims to fund these programs through its lean financial platform and partnerships.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the progress and timeline for CIC and flu partnership discussions, citing the sensitive nature of such conversations. They also did not comment on Sanofi's progress or the specifics of BARDA's evolving framework.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
CIC arm
CIC flu
Corporate Participant
Executive VP
LLC
PMC study
RD SGA
Research Division
Serum
Slide
Takeda
administration
authorization
cell
commitment study
discussion
dos
dose
framework
generation
increase
influenza
insight
malaria vaccine
need
partner reimbursement
partnership
payment
period
potential
priority
profitability
progress
role
scale
statement
supply sale
transfer
use
vaccine candidate
NVAX Transcript
Novavax, Inc. (NVAX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-4
Novavax, Inc. (NVAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Novavax, Inc. (NVAX) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call summary highlights a 12% YoY revenue increase and improved net loss, reflecting strong financial performance. The strategic initiatives and partnerships indicate potential growth, while the cash increase suggests financial health. Despite regulatory and strategic risks, the overall outlook is optimistic. No negative sentiment from the Q&A section further supports a positive rating.
Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
NVAX Slides
NVAX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
